202 related articles for article (PubMed ID: 28193211)
1. Display of single-chain variable fragments on bacteriophage MS2 virus-like particles.
Lino CA; Caldeira JC; Peabody DS
J Nanobiotechnology; 2017 Feb; 15(1):13. PubMed ID: 28193211
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.
Peabody DS; Manifold-Wheeler B; Medford A; Jordan SK; do Carmo Caldeira J; Chackerian B
J Mol Biol; 2008 Jun; 380(1):252-63. PubMed ID: 18508079
[TBL] [Abstract][Full Text] [Related]
3. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
Ashley CE; Carnes EC; Phillips GK; Durfee PN; Buley MD; Lino CA; Padilla DP; Phillips B; Carter MB; Willman CL; Brinker CJ; Caldeira Jdo C; Chackerian B; Wharton W; Peabody DS
ACS Nano; 2011 Jul; 5(7):5729-45. PubMed ID: 21615170
[TBL] [Abstract][Full Text] [Related]
4. Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.
Crossey E; Frietze K; Narum DL; Peabody DS; Chackerian B
PLoS One; 2015; 10(7):e0132560. PubMed ID: 26147502
[TBL] [Abstract][Full Text] [Related]
5. Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles.
Chackerian B; Caldeira Jdo C; Peabody J; Peabody DS
J Mol Biol; 2011 Jun; 409(2):225-37. PubMed ID: 21501621
[TBL] [Abstract][Full Text] [Related]
6. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles.
Pan Y; Zhang Y; Jia T; Zhang K; Li J; Wang L
FEBS J; 2012 Apr; 279(7):1198-208. PubMed ID: 22309233
[TBL] [Abstract][Full Text] [Related]
7. Assessing Antibody Specificity in Human Serum Using Deep Sequence-Coupled Biopanning.
Frietze KM; Core SB; Linville A; Chackerian B; Peabody DS
Methods Mol Biol; 2020; 2070():157-171. PubMed ID: 31625095
[TBL] [Abstract][Full Text] [Related]
8. Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma.
Wang G; Jia T; Xu X; Chang L; Zhang R; Fu Y; Li Y; Yang X; Zhang K; Lin G; Han Y; Li J
Oncotarget; 2016 Sep; 7(37):59402-59416. PubMed ID: 27449085
[TBL] [Abstract][Full Text] [Related]
9. Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.
O'Rourke JP; Peabody DS; Chackerian B
Curr Opin Virol; 2015 Apr; 11():76-82. PubMed ID: 25829254
[TBL] [Abstract][Full Text] [Related]
10. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
11. Dual Surface Modification of Genome-Free MS2 Capsids for Delivery Applications.
Aanei IL; Francis MB
Methods Mol Biol; 2018; 1776():629-642. PubMed ID: 29869270
[TBL] [Abstract][Full Text] [Related]
12. A novel delivery platform based on Bacteriophage MS2 virus-like particles.
Fu Y; Li J
Virus Res; 2016 Jan; 211():9-16. PubMed ID: 26415756
[TBL] [Abstract][Full Text] [Related]
13. MS2 Virus-like Particles as a Versatile Peptide Presentation Platform: Insights into the Deterministic Abilities for Accommodating Heterologous Peptide Lengths.
Dang M; Wu LJ; Zhang SR; Zhu JR; Hu YZ; Yang CX; Zhang XY
ACS Synth Biol; 2023 Dec; 12(12):3704-3715. PubMed ID: 37946498
[TBL] [Abstract][Full Text] [Related]
14. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology.
Tohidkia MR; Asadi F; Barar J; Omidi Y
BioDrugs; 2013 Feb; 27(1):55-67. PubMed ID: 23344946
[TBL] [Abstract][Full Text] [Related]
15. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique.
Aghebati-Maleki L; Younesi V; Jadidi-Niaragh F; Baradaran B; Majidi J; Yousefi M
Hum Antibodies; 2017; 25(1-2):57-63. PubMed ID: 28128766
[TBL] [Abstract][Full Text] [Related]
17. A One-Step Process for the Construction of Phage Display scFv and VHH Libraries.
Sellmann C; Pekar L; Bauer C; Ciesielski E; Krah S; Becker S; Toleikis L; Kügler J; Frenzel A; Valldorf B; Hust M; Zielonka S
Mol Biotechnol; 2020 Apr; 62(4):228-239. PubMed ID: 31981039
[TBL] [Abstract][Full Text] [Related]
18. Production and applications of fluorobody from redox-engineered Escherichia coli.
Srila W; Min TT; Sumphanapai T; Rangnoi K; Berkmen M; Yamabhai M
Appl Microbiol Biotechnol; 2023 Mar; 107(5-6):1959-1970. PubMed ID: 36729226
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells.
Naskalska A; Heddle JG
Nanomedicine (Lond); 2024; 19(12):1103-1115. PubMed ID: 38629576
[TBL] [Abstract][Full Text] [Related]
20. Production in Saccharomycescerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs.
Legendre D; Fastrez J
J Biotechnol; 2005 May; 117(2):183-94. PubMed ID: 15823407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
